PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. - Wikidata - awgldk - TriplyDB

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

http://www.wikidata.org/entity/Q40216708

about

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.Checking up on checkpoint inhibitors.Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.TNFR2: The new Treg switch?Hodgkin lymphoma: A review and update on recent progress.Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.Clinical Development of PD-1 Blockade in Hematologic Malignancies.Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.Transplant strategies in relapsed/refractory Hodgkin lymphoma.Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia

P2860

Q38700459-0946CDE4-30DD-413F-94CF-36B3BE684E33 Q41017116-93E19DF6-A856-4FD7-9069-7A6F96EE44A2 Q47329066-FEC4EB81-23C7-49FB-9573-D07B9A425D96 Q47381937-57195E05-93AA-464E-8C9B-880EFB820E87 Q47807176-048B01D0-7774-4EEA-8D99-58657C868D63 Q47855599-56FE3D12-1D6D-4E14-85A2-6C499528FC08 Q47952363-C460707D-E828-4C28-9853-ADF135553FC5 Q48165202-6C98DC1C-9F9A-4260-986E-8970996F89EC Q48273861-20F227FB-9F51-4F74-8637-706D8CA82304 Q48526801-A6C34E41-CD3F-4F31-8FED-F021A83DEAF0 Q49900727-681F441A-EC8D-4BFD-94B7-D59B92034E5B Q52676516-4202F88F-75D0-416F-8A61-429BE1CC1D2D Q52721221-1B4D2FB4-4264-4B2E-81FB-07771FE4BAA7 Q52763883-12AD19B3-1A09-49AC-96B7-CC40B5D542DD Q58761583-88CD93B1-26F1-42B7-A9F0-59B8E5BA1335 Q58799058-695318F7-BAE6-4FAC-BA00-AD532C2EF882

P2860

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

http://www.wikidata.org/entity/Q40216708

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

PD-1 blockade for relapsed lym ...... sponse rate but frequent GVHD.

@en

type

label

PD-1 blockade for relapsed lym ...... sponse rate but frequent GVHD.

@en

prefLabel

PD-1 blockade for relapsed lym ...... sponse rate but frequent GVHD.

@en

P1433

Q40216708-B89E6EC2-A90B-4A11-AF40-5CF5B02D33B1

P1476

Q40216708-1D8EC085-19A6-4AA7-A588-49F75517DB5C

P2093

Q40216708-05096567-477B-44A8-ACA7-497FB204155E

Q40216708-092C73F2-9365-49DE-BE57-EDFF93AD2C31

Q40216708-0A3EE610-9937-444C-85FB-7F7A5E51648C

Q40216708-0CCC93E3-65E9-470D-AF0F-C99A415105F8

Q40216708-151C4895-7A9B-417F-92D4-5059A19C6401

Q40216708-224DCFAD-449A-45C3-AF61-2790629AE36F

Q40216708-2A293B33-4C2E-491B-8DAB-5B66D77F3201

Q40216708-3DBF4625-C4BE-4EE2-A2ED-EC428DC6075E

Q40216708-49F3502D-37A2-4CBD-8BC4-E57DE66F490F

Q40216708-6B9A4700-0659-49A5-8792-7303BEB2A91F

P2860

Q40216708-01813AB4-F987-4F9A-BA51-40BD5662548B

Q40216708-0286712C-BAE9-4436-9209-6DBA79C790F3

Q40216708-046D1BD9-E966-4096-893E-0FDFFD31ACD5

Q40216708-0872C4A0-2FD7-4E60-89F6-FAB0213BC5D1

Q40216708-098459C9-6A95-4986-A060-1F5FBC9E5ED7

Q40216708-19B9F96C-D74D-4AAC-B8E4-38FAF0A1F92E

Q40216708-1A379458-D9C9-46DE-9FFF-214BDC49FB7A

Q40216708-1EF73650-9E5C-4F05-808F-7A535F17D585

Q40216708-2330AAE6-23AC-4777-A158-5D86D049BECA

Q40216708-2635F435-E68B-4938-9812-781EF68036D8

P304

Q40216708-796F99B1-42D1-4550-84E3-FCC2450DFD87

P31

Q40216708-5051EB16-3859-4C5D-8A5D-6E3DC24BCEC6

P356

Q40216708-2B3E0B52-00D9-442F-A4EB-B3DDF98BE52C

P407

Q40216708-D0C9B722-91EA-4E4C-A888-C6B448881CBD

P433

Q40216708-987259BE-4640-44FC-ABE2-0DC7B60A70DF

P478

Q40216708-B1595325-B9A5-47DA-BE20-FFAD4AA53684

P50

Q40216708-542D32AB-FDB3-4C31-9AE8-45A613B241A0

Q40216708-9BDEF883-36FA-4D49-A07F-83C7C000AD37

Q40216708-ED4D8832-363C-4A91-9212-7A9E8DE06CDE

P577

Q40216708-2E5C8D0B-6C95-4B76-BC4D-D5DBAA394CF3

P698

Q40216708-FC915FAA-FA17-44F2-A215-E7475AFCB20E

P932

Q40216708-B0FF1F83-BB6E-4DB5-A679-ACD3819AFB91

P356

BLOOD-2017-01-761346

P1433

P1476

PD-1 blockade for relapsed lym ...... esponse rate but frequent GVHD

@en

P2093

Abraham Sebastian Kanate

http://www.w3.org/2001/XMLSchema#string

Amitkumar Mehta

http://www.w3.org/2001/XMLSchema#string

Asad Bashey

http://www.w3.org/2001/XMLSchema#string

Ayman Saad

http://www.w3.org/2001/XMLSchema#string

Bruce R Blazar

http://www.w3.org/2001/XMLSchema#string

Diana Abbott

http://www.w3.org/2001/XMLSchema#string

Jonathan Gutman

http://www.w3.org/2001/XMLSchema#string

Leslie Andritsos

http://www.w3.org/2001/XMLSchema#string

Madan Jagasia

http://www.w3.org/2001/XMLSchema#string

Manali Kamdar

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Advances in graft-versus-host disease biology and therapy.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

P304

221-228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2017-01-761346

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

Veronika Bachanova

Deborah M Stephens

Bradley M Haverkos

P577

2017-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28468799

http://www.w3.org/2001/XMLSchema#string

P932

5510790

http://www.w3.org/2001/XMLSchema#string